Biocardia, INC Form 4 insider transactions

BioCardia's President and CEO, Peter Altman, recently purchased 500 shares of the company's common stock at an average price of $1.96 per share.

BioCardia's CEO, Peter Altman, recently purchased 800 shares of the company's common stock at an average price of $2.04 per share.

BioCardia's CEO, Peter Altman, recently purchased additional shares of the company's common stock, increasing his beneficial ownership.

BioCardia's President and CEO, Peter Altman, recently purchased 1,200 shares of the company's common stock at an average price of $2.24 per share.

Director Simon H. Stertzer purchased 1,000 shares of BioCardia, Inc. common stock at $2.45 per share on March 5, 2025.

Director Simon H. Stertzer reports purchasing additional shares of BioCardia, Inc. common stock in recent transactions.

BioCardia's CEO, Peter Altman, recently purchased 500 shares of the company's common stock at an average price of $2.11 per share.

BioCardia's President and CEO, Peter Altman, recently purchased 600 shares of the company's common stock at an average price of $2.48 per share.

BioCardia's President and CEO, Peter Altman, has acquired a total of 739 shares of common stock through open market purchases on January 29th and 30th, 2025.

BioCardia's President and CEO, Peter Altman, purchased 1,000 shares of common stock at a price of $2.06 per share on December 23, 2024.

A BioCardia executive, Edward M. Gillis, sold 3,257 shares of common stock for tax planning purposes.

BioCardia's President and CEO, Peter Altman, purchased 250 shares of common stock at an average price of $2.22 per share on December 5, 2024.

BioCardia's President and CEO, Peter Altman, purchased 1,350 shares of common stock at $1.87 per share on November 15, 2024.

Senior Vice President of Devices at BioCardia, Edward Gillis, reports acquisition and disposal of common stock related to vested restricted stock units.

Peter Altman, CEO of BioCardia, acquired shares through vested restricted stock units and had shares withheld for tax obligations.

Andrew Scott Blank, a director at BioCardia, Inc., was granted stock options to purchase 829 shares of common stock at an exercise price of $2.65 on October 11, 2024.

BioCardia's Chief Financial Officer, David McClung, reports the acquisition and disposal of common stock related to vested restricted stock units.

Director Jay M. Moyes acquired stock options for 829 shares of BioCardia, Inc. at an exercise price of $2.65 on October 11, 2024.

Director Bill Facteau reports the acquisition of stock options in BioCardia, Inc.

Director Simon H. Stertzer acquired stock options in BioCardia, Inc. on October 11, 2024.

Director Richard M. Krasno acquired stock options in BioCardia, Inc. on October 11, 2024.

Director Jim L. Allen acquired stock options in BioCardia, Inc. on October 11, 2024.

BioCardia's Chief Financial Officer, David McClung, reports purchasing shares and warrants in a recent public offering.

Director Andrew Blank increased his stake in BioCardia through a recent public offering, acquiring 111,000 shares and warrants.

BioCardia's CEO, Peter Altman, acquired 41,666 shares of common stock and warrants in a recent public offering.

Director Jim L. Allen reports acquisition of 50,000 shares of BioCardia, Inc. common stock and warrants in a public offering.

BioCardia's President and CEO, Peter Altman, recently purchased additional shares of the company's common stock, signaling confidence in the firm.

BioCardia's President and CEO, Peter Altman, purchased 500 shares of the company's common stock at an average price of $3.29 on June 21, 2024.

BioCardia's President and CEO, Peter Altman, recently purchased 500 shares of the company's common stock at an average price of $3.52 per share.

BioCardia's President and CEO, Peter Altman, recently purchased 1,000 shares of the company's common stock at an average price of $3.36 per share.